Recursion Pharmaceuticals RXRX, a TechBio company that decodes biology and chemistry to industrialize drug discovery, is expected to report fourth-quarter 2025 results soon. The Zacks Consensus ...

The biotechnology firm reported a loss per share of 21 cents, surpassing the estimated loss of 27 cents. Additionally, Recursion’s revenue reached $35.54 million in the quarter, well above the ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

Nvidia disclosed in recent regulatory filings that it had fully exited its roughly two‑year, 7.71 million‑share investment in Recursion Pharmaceuticals, while Cathie Wood’s ARK Invest simultaneously ...

Nvidia's positions in these companies were relatively small at the end of the third quarter of 2025, but the chipmaker has spent recent years building a portfolio of AI‑related investments across ...

Delivered first clinical validation of the Recursion full stack AI Operating System in FAP, demonstrating translation from AI-driven biological insight to meaningful patient outcomes; multiple clinica ...

Shares of Recursion Pharmaceuticals (RXRX) spiked on Wednesday after the AI-driven drug developer significantly exceeded Street forecasts with its Q4 2025 financials, thanks primarily to a milestone ...

Recursion Pharmaceuticals reports fourth-quarter and full-year 2025 results Wednesday before the market opens, with investors scrutinizing whether the AI-driven biotech can translate its massive data ...